Ionis Pharma (IONS) Tops Q4 EPS by 33c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. LBRX
2. MRK
3. TRAX
4. LMT
5. FATE
6. KTOS
7. FFAI
8. IRIX
9. BRO
10. AON

Go back to Ionis Pharma (IONS) Tops Q4 EPS by 33c

Ionis' 2016 Financial Results Outperform Financial Guidance

February 28, 2017 7:00 AM EST

CARLSBAD, Calif., Feb. 28, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported that it outperformed its financial guidance by ending 2016 with pro forma operating income of $25.8 million and $665.2 million in cash, cash equivalents and short-term investments. The Company also reported a GAAP loss from operations of $46.3 million.

"2016 was a year of significant accomplishments for Ionis, culminating in the U.S. approval of SPINRAZA, in record time and with a very broad label. The approval of SPINRAZA is a... More